Stockscreener 앱 받기
8.97
5.04%
0.43
시간 외 거래:
8.97
전일 마감가:
$8.54
열려 있는:
$8.62
하루 거래량:
1.09M
Relative Volume:
1.01
시가총액:
$449.94M
수익:
$89.04M
순이익/손실:
$-241.08M
주가수익비율:
-1.7053
EPS:
-5.26
순현금흐름:
$-194.72M
1주 성능:
-9.03%
1개월 성능:
-4.68%
6개월 성능:
-9.58%
1년 성능:
-36.43%
1일 변동 폭
$8.43
$9.29
1주일 범위
$8.43
$9.83
52주 변동 폭
$5.035
$15.36
Regenxbio Inc Stock (RGNX) Company Profile
명칭
Regenxbio Inc
전화
240-552-8181
주소
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
RGNX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RGNX
Regenxbio Inc
|
8.97 | 494.58M | 89.04M | -241.08M | -194.72M | -5.26 |
|
ONC
Beone Medicines Ltd Adr
|
246.68 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.09 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.30 | 40.37M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.39 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
77.49 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
Regenxbio Inc Stock (RGNX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-11 | 다운그레이드 | Goldman | Buy → Neutral |
| 2025-02-07 | 재개 | Raymond James | Outperform |
| 2024-11-15 | 재개 | Morgan Stanley | Overweight |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-06-07 | 개시 | Goldman | Buy |
| 2024-03-11 | 개시 | H.C. Wainwright | Buy |
| 2024-03-08 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-03-06 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-02-21 | 재개 | Raymond James | Outperform |
| 2023-11-01 | 개시 | Stifel | Buy |
| 2023-06-02 | 개시 | Robert W. Baird | Outperform |
| 2022-06-23 | 개시 | Berenberg | Buy |
| 2021-12-15 | 개시 | Wedbush | Neutral |
| 2021-10-19 | 재개 | Morgan Stanley | Overweight |
| 2021-01-06 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2020-12-16 | 개시 | UBS | Buy |
| 2020-06-25 | 재개 | BofA/Merrill | Buy |
| 2020-05-13 | 개시 | RBC Capital Mkts | Sector Perform |
| 2019-08-20 | 업그레이드 | SVB Leerink | Underperform → Mkt Perform |
| 2019-06-18 | 재확인 | Chardan Capital Markets | Buy |
| 2019-06-14 | 재개 | Raymond James | Outperform |
| 2019-06-05 | 재확인 | Chardan Capital Markets | Buy |
| 2019-02-25 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2019-02-05 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2018-12-17 | 재확인 | Chardan Capital Markets | Buy |
| 2018-11-08 | 재확인 | BofA/Merrill | Neutral |
| 2018-08-08 | 재확인 | Chardan Capital Markets | Buy |
| 2018-07-23 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2018-07-10 | 재확인 | Chardan Capital Markets | Buy |
| 2018-05-09 | 재확인 | Barclays | Overweight |
| 2018-04-09 | 재확인 | Chardan Capital Markets | Buy |
| 2018-03-12 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2018-02-13 | 개시 | Mizuho | Neutral |
| 2017-11-09 | 재개 | Morgan Stanley | Overweight |
모두보기
Regenxbio Inc 주식(RGNX)의 최신 뉴스
REGENXBIO announces royalty monetization agreement for up to $250M - MSN
REGENXBIO’s SWOT analysis: gene therapy firm’s stock poised for growth - Investing.com Australia
REGENXBIO’s SWOT analysis: gene therapy firm’s stock poised for growth By Investing.com - Investing.com South Africa
REGENXBIO’s $250 Million Royalty Bond Agreement with HealthCare Royalty - Global Legal Chronicle
Coave Therapeutics Establishes New Scientific Advisory Board to Accelerate Innovation in Genetic Medicines for Eye and CNS Diseases - GlobeNewswire Inc.
Regenxbio at RBC Conference: Strategic Moves and Clinical Progress - Investing.com Australia
Regenxbio at RBC Conference: Strategic Moves and Clinical Progress By Investing.com - Investing.com Nigeria
REGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 Million | RGNX Stock News - GuruFocus
Stifel maintains Buy on Regenxbio, price target at $40 By Investing.com - Investing.com Nigeria
Stifel maintains Buy on Regenxbio, price target at $40 - Investing.com
Regenxbio Secures $250 Million In New Royalty Bonds - Finimize
REGENXBIO secures $150 million to extend cash runway By Investing.com - Investing.com South Africa
Regenxbio (RGNX) Secures $250M Royalty Bond Deal for Non-Dilutiv - GuruFocus
REGENXBIO (RGNX) Secures $250 Million Non-Dilutive Funding - GuruFocus
REGENXBIO secures $150 million to extend cash runway - Investing.com Australia
RegenXBio Secures $250M Royalty Monetization Deal - TipRanks
REGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 Million - Eagle-Tribune
Regenxbio Announces Strategic Royalty Monetization Agreement For Up To $250 Million - marketscreener.com
REGENXBIO's $250M Royalty Deal Extends Cash Runway to 2027, Funds Multiple Late-Stage Programs - Stock Titan
Regenxbio signals RGX-202 pivotal enrollment surpasses 50% as company initiates commercial manufacturing in Q3 2025 - MSN
REGENXBIO’s Earnings Call Highlights Strong Start to Fiscal Year - TipRanks
REGENXBIO’s BLA for MPS II Gene Therapy RGX-121 Accepted for Priority Review by the FDA - CGTLive®
REGENXBIO Inc. Just Missed EPS By 64%: Here's What Analysts Think Will Happen Next - simplywall.st
Regenxbio BLA for Hunter syndrome candidate accepted by FDA - MSN
(RGNX) Proactive Strategies - news.stocktradersdaily.com
Earnings Miss: REGENXBIO Inc. Missed EPS By 64% And Analysts Are Revising Their Forecasts - Yahoo Finance
REGENXBIO Inc. (NASDAQ:RGNX) Q1 2025 Earnings Call Transcript - Insider Monkey
FDA Grants Priority Review to REGENXBIO's (RGNX) Gene Therapy fo - GuruFocus
FDA Accepts Biologics License Application For Mucopolysaccharidosis II Treatment - marketscreener.com
FDA Grants Priority Review to REGENXBIO's (RGNX) Gene Therapy for MPS II | RGNX Stock News - GuruFocus
FDA Accepts Biologics License Application for Mucopolysaccharidosis II Treatment - Eastern Progress
US FDA accepts Regenxbio’s application for MPS II gene therapy - World Pharmaceutical Frontiers
Earnings call transcript: Regenxbio Q1 2025 misses forecasts, stock rises By Investing.com - Investing.com Nigeria
Stifel maintains buy on Regenxbio, reiterates $40 target - Investing.com Australia
Regenxbio (RGNX) Gains FDA Priority Review for RGX-121 BLA | RGN - GuruFocus
Transcript : REGENXBIO Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 05 - marketscreener.com
Stifel maintains buy on Regenxbio, reiterates $40 target By Investing.com - Investing.com India
REGENXBIO (RGNX) Reports Decrease in Q1 Revenue, Focuses on Gene Therapy Progress | RGNX Stock News - GuruFocus
REGENXBIO Reports First Quarter 2025 Financial Results and Recen - GuruFocus
Regenxbio Says Potential Hunter Syndrome Treatment Granted FDA Priority Review - marketscreener.com
Regenxbio stock rises on FDA’s priority review for MPS II therapy - Investing.com Nigeria
Regenxbio stock rises on FDA’s priority review for MPS II therapy By Investing.com - Investing.com South Africa
Regenxbio Announces FDA Acceptance And Priority Review Of BLA For Rgx-121 For Mps Ii - marketscreener.com
REGENXBIO Announces FDA Acceptance and Priority Review of the BL - GuruFocus
Regenxbio Inc (RGNX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.95%
자본화:
|
볼륨(24시간):